| Literature DB >> 20351309 |
Jinjoo Kang1, Jaehyuk Yoo, Sunju Lee, Wanli Tang, Berenice Aguilar, Swapnika Ramu, Inho Choi, Hasan H Otu, Jay W Shin, G Paolo Dotto, Chester J Koh, Michael Detmar, Young-Kwon Hong.
Abstract
Arteriovenous-lymphatic endothelial cell fates are specified by the master regulators, namely, Notch, COUP-TFII, and Prox1. Whereas Notch is expressed in the arteries and COUP-TFII in the veins, the lymphatics express all 3 cell fate regulators. Previous studies show that lymphatic endothelial cell (LEC) fate is highly plastic and reversible, raising a new concept that all 3 endothelial cell fates may co-reside in LECs and a subtle alteration can result in a reprogramming of LEC fate. We provide a molecular basis verifying this concept by identifying a cross-control mechanism among these cell fate regulators. We found that Notch signal down-regulates Prox1 and COUP-TFII through Hey1 and Hey2 and that activated Notch receptor suppresses the lymphatic phenotypes and induces the arterial cell fate. On the contrary, Prox1 and COUP-TFII attenuate vascular endothelial growth factor signaling, known to induce Notch, by repressing vascular endothelial growth factor receptor-2 and neuropilin-1. We show that previously reported podoplanin-based LEC heterogeneity is associated with differential expression of Notch1 in human cutaneous lymphatics. We propose that the expression of the 3 cell fate regulators is controlled by an exquisite feedback mechanism working in LECs and that LEC fate is a consequence of the Prox1-directed lymphatic equilibrium among the cell fate regulators.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20351309 PMCID: PMC2904577 DOI: 10.1182/blood-2009-11-252270
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113